Board of the College of Pharmacists of British Columbia Regulation

B.C. Reg. 227/2022: Amendments to the Drug Schedules Regulation

Made under the Pharmacy Operations and Drug Scheduling Act

How does this rule affect your organization? One Click reads it against your profile and tells you, on Canada Federal Legislative Tracking. See plans →

Get alerted when the next rule lands

New rules land on their own schedule. Pick how you want to hear about them — we email you when one appears.

Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.

The rule, in full

365 words as published, December 06, 2022. View the original →

B.C. Reg. 227/2022, deposited November 23, 2022, under the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22]. Resolution of the Board of the College of Pharmacists of British Columbia, dated September 23, 2022. The Board of the College of Pharmacists of British Columbia orders that the Drug Schedules Regulation, B.C. Reg. 9/98, is amended as set out in the attached Appendix. — S. HOPP, Chair, Board of the College of Pharmacists of British Columbia.

Appendix

1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules (a) by striking out the following: 1 Brimonidine and its salts 2 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days, (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and (b) in package sizes containing greater than 2.6 g of diclofenac diethylamine 3 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days, (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and (b) in package sizes containing no more than 2.6 g of diclofenac diethylamine 2 Strontium and its salts in injectable form , and (b) by adding the following: 1 Brimonidine or its salts (except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older) 3 Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older 3 Diclofenac diethylamine, for human use, when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days, (a) in concentrations greater than 1.16% and less than or equal to 2.32%, and (b) in package sizes containing greater than 2.6 g of diclofenac diethylamine 1 Sotrovimab 2 Strontium and its salts in injectable form (except strontium bromide) .